Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab
Information source: University of Sao Paulo
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Age Related Macular Degeneration; Diabetic Retinopathy
Intervention: Acetazolamide (Drug); Brimonidine tartarate (Drug); Anterior chamber paracentesis (Procedure)
Phase: Phase 2
Status: Completed
Sponsored by: University of Sao Paulo Official(s) and/or principal investigator(s):
Rodrigo Jorge, MD, Study Chair, Affiliation: University of São Paulo
Marco A Bonini-Filho, MD, Principal Investigator, Affiliation: University of São Paulo
Bianka Y Katayama, MD, Study Director, Affiliation: Clinic´s Hospital, Ribeirão Preto Medical School, University of São Paulo
Summary
The purpose of this study is to evaluate the effects of anterior chamber paracentesis,
brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after
intravitreal bevacizumab injection.
Clinical Details
Official title: Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab Injection
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Intraocular pressure (mmHg)
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosis of age related macular disease or diabetic retinopathy
- Able and willing to provide informed consent
Exclusion Criteria:
- History of ocular hypertension or glaucoma
- High Myopes (> 6 spherical diopters)
- High Hyperopes (> 4 spherical diopters)
- Pulmonary disease
- Renal disease
- Known allergy to any component of the study drug
- Myocardial infarction, transient ischemic attack within 4 months prior to
randomization or any contraindication for bevacizumab use
Locations and Contacts
Additional Information
Starting date: June 2008
Last updated: March 18, 2009
|
